chugai

At BIO Asia–Taiwan 2025, Plenary Session 3 Panel Discussion brought together leading voices in pharma, biotech, and clinical innovation to explore “The Value of Innovation for a Healthier Taiwan.” Moderated by Dr. Johnsee Lee, Chairman of BIO Asia–Taiwan 2025, the panel examined how innovative science, policy alignment, and cross-sector collaboration are shaping Taiwan’s health ecosystem. Panelists included Yuji Habara, President & General Manager of Chugai Pharma Taiwan; Tina Graves, VP and General Manager of GSK Taiwan; Sayaka Fukura, Deputy Head of the Clinical Operations Division at CMIC; and Luke Bi, Executive Director and Head of China BioA and APAC LCMS at Labcorp. Each speaker brought distinct insights to a common challenge: how to unlock the value of innovation for real-world health outcomes.

Chugai Pharma Taiwan, a century-old enterprise (Chugai Pharmaceutical CO.,LTD.), grandly held its "100th Anniversary Family Day" event on June 29th at Yuanshan Flora Expo Park. The celebration brought together nearly 200 employees, retirees, and their families from across Taiwan to witness this glorious milestone moment together. The event was filled with warmth and gratitude.

The birth of a century-old enterprise is no coincidence. Since its establishment, Chugai has weathered changing times and market fluctuations while steadfastly adhering to its "patient-centered" philosophy. Through continuous innovation and steady growth, the company has remained resilient in the fiercely competitive pharmaceutical industry. This Family Day event was not only a celebration but also a heartfelt expression of gratitude to all employees and their families, representing the most touching manifestation of corporate culture.

Embracing talent, we can do even better. Talent sustainability has always been a goal we value. To create a more diverse, equal, and inclusive workplace, we are officially announcing again that Chugai Pharma Taiwan is joining the "2025 TALENT, in Taiwan, Taiwan Talent Sustainability Action Alliance."

This year, Chugai Pharma Taiwan (CPT) has officially partnered with Blueseeds, a local Taiwanese sustainability brand, to adopt and support organic herb farms, reinforcing the company's commitment to corporate sustainability (ESG). Recently, company executives traveled to Taitung to attend the official adoption ceremony, meet with contract farmers, and experience firsthand the natural beauty of the organic herb fields.

Chugai Pharma Taiwan has been honored with the "Procurement Innovation Pioneer Award" by the Taipei City Government, recognizing its proactive efforts in procuring products and services from local startups and small and medium-sized enterprises (SMEs). This achievement underscores the company’s commitment to fostering innovation and contributing to Taipei's industrial development.

Chugai Pharma Taiwan convened its board of directors meeting in December of 2024, during which all board members unanimously resolved to appoint Mr. Yuji Habara as the new President, effective January 1st of 2025.

With extensive management experience and profound expertise in the pharmaceutical and biotechnology industries, President Yuji Habara is expected to lead Chugai Pharma Taiwan toward continued steady progress in achieving the group's vision. Under his leadership, the company will not only bring innovative products to patients but also actively contribute to society, safeguard human health and well-being, and strive for excellence.

Chugai Pharma Taiwan (CPT) is dedicated to fulfilling its corporate social responsibilities. In addition to engaging in charitable endeavors, it takes a cautious approach when evaluating supplier qualifications, opting for top-quality and eco-friendly products. Through the implementation of responsible purchasing practices, it has received commendation from the Ministry of Economic Affairs, earning the distinguished "2024 Buying Power Procurement Award".